SGLT2 inhibitors showed significantly improved mortality benefits compared with DPP-4 inhibitors in patients with diabetic kidney disease (DKD) in a large target trial emulation study that adds ...

person doing fingertip test for blood glucose, with vacuum tube for blood testing of test blood with covid-19 label Investigators aimed to determine the association of pre-existing DPP-4is use with ...

- Interim analysis of the EMPRISE real-world evidence study showed that empagliflozin was associated with a reduced risk in all-cause mortality, hospitalization for heart failure and acute kidney ...

Initiation of sodium-glucose cotransporter-2 inhibitors (SGLT2is) was associated with a 34% lower rate of recurrent gout flare compared with initiation of dipeptidyl peptidase 4 inhibitors (DPP-4is).

Severe Hypoglycemia Ups Cardiovascular Risk in Diabetes Two studies demonstrate no difference versus placebo for saxagliptin, alogliptin. For patients with type 2 diabetes, treatment with the ...

The study published in eClinicalMedicine by Huilin Tang and colleagues from the University of Pennsylvania Perelman School of ...

With regards to his pioglitazone use, he had no history of heart failure, and his ALT level was acceptable at the time of discharge at 25 U/L. Signs and symptoms of heart failure were reviewed with ...

The American College of Physicians issued new guidelines for Type 2 diabetes treatment, which for the first time recommends the use of GLP-1s and another class of diabetes drugs called SGLT-2s ...

GLP-1 receptor agonist use may be associated with a modest increase in erectile dysfunction (ED) risk in men with type 2 ...